Asklep Inc. (Headquarters: Toshima-ku, Tokyo, Japan, Representative Director and President: Yuichi Yahagi) announced today the formation of a capital tie-up with Kyoto Constella Technologies Co., Ltd. (Nakagyo-ku, Kyoto-shi, Kyoto, Japan, President and CEO: Ryuta Murakami) on May 15th, 2015.
Intage Holdings Inc. (parent company of Asklep) has had a capital tie-up with Kyoto Constella Technologies since October 2014. The addition of Asklep’s capital participation allows further expansion of our pharmacovigilance service and enables us to work together in the support of drug research and development and strengthen our ties with Kyoto Contstella.
The scope of pharmacovigilance service is expanding and the need for expertise in the field has been increasing. Pharmacovigilance no longer requires merely the collection of adverse events information but now includes the design of risk management plans (RMP) for drugs. Asklep offers high value-added solution-focused services through extensive experience and knowhow in data collection, post-marketing surveillance, and clinical trials. This capital tie-up enables us to offer a wider range of services to our clients, from consultation to pharmacovigilance systems, by linking our service to in-house developed database search systems for adverse drug reaction information (CzeekR and CzeekV).
Kyoto Constella Technologies provides service in efficient drug discovery research and products such as in silico compound screening for drug candidates (CzeekS) and de novo compound design system (CzeekD). Asklep will link these systems and services with clinical trials, post-marketing surveillance and pharmacovigilance as well as the healthcare-related services by the Intage Group and thus enable us to provide a complete and consistent support for the lifecycle of drugs.
We are determined to make a valuable contribution to the further development of drug research and development by the synergistic combination of the two companies’ “intelligence” in pharmacovigilance and drug discovery research.
Asklep offers high value-added medical intelligence through its drug development, post-marketing surveillance and pharmacovigilance services. With our core value of further optimizing the Quality of Life of patients, we strive to enhance the value of medical data and information and deliver highly value-added solutions in the role of Medical Intelligence Provider.
Kyoto Constella Technologies was established in March 2008, as a venture company from Kyoto University. Aiming to support the drug discovery efforts of research institutes and pharmaceutical companies and to develop a database of drug adverse reaction information, we offer products and services based on our core technology developed by Professor Yasushi Okuno of Kyoto University combined with state-of-the-art computational technology.